Review
Pediatrics
So Yoon Choi, Ben Kang
Summary: The introduction of biological agents, particularly anti-TNF agents, has significantly improved the long-term prognosis of patients with inflammatory bowel disease (IBD). In pediatric populations, only two biological agents, infliximab (IFX) and adalimumab (ADL), have been approved for use. ADL has shown efficacy in achieving mucosal healing (MH) and histological remission in both naive patients and those who have previously received biologic treatment. Therapeutic drug monitoring may further enhance the effectiveness of ADL treatment and reduce treatment failure.
FRONTIERS IN PEDIATRICS
(2022)
Article
Medicine, General & Internal
Alice Burgevin, Benedicte Caron, Alexa Sasson, Amandine Luc, Patrick Netter, Cedric Baumann, Ashwin N. Ananthakrishnan, Laurent Peyrin-Biroulet
Summary: The safety of vedolizumab and ustekinumab therapies in older patients with inflammatory bowel disease was compared. The study found that there was no difference in terms of safety between vedolizumab and ustekinumab in patients with Crohn's disease. The occurrence of adverse events per year of follow-up was also similar between vedolizumab and anti-TNF therapy for ulcerative colitis and Crohn's disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Immunology
Yiyoung Kwon, Yoon Zi Kim, Yon Ho Choe, Mi Jin Kim
Summary: This study found that patients with high monocyte counts at the time of discontinuation were more likely to experience relapse after stopping biologics. The monocyte percentage can be used to predict the risk of relapse within 6 months after discontinuation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Gastroenterology & Hepatology
Ole Haagen Nielsen, John Mark Gubatan, Carsten Bogh Juhl, Sarah Elizabeth Streett, Cynthia Maxwell
Summary: Adverse pregnancy outcomes among pregnant IBD women using biologics are comparable with that of the general population.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Daniela Pugliese, Giuseppe Privitera, Federica Crispino, Nicolo Mezzina, Fabiana Castiglione, Gionata Fiorino, Lucrezia Laterza, Anna Viola, Lorenzo Bertani, Flavio Caprioli, Maria Cappello, Brigida Barberio, Chiara Ricci, Paola Balestrieri, Marco Daperno, Dario Pluchino, Fernando Rizzello, Maria Lia Scribano, Renato Sablich, Luca Pastorelli, Francesco Manguso, Angela Variola, Antonio Di Sario, Laurino Grossi, Alessandro Armuzzi
Summary: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients. No significant difference in effectiveness was observed between elderly and nonelderly CD patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Ohad Atia, Sasha Harel, Natan Ledderman, Shira Greenfeld, Revital Kariv, Iris Dotan, Ran Balicer, Barbara Silverman, Eran Matz, Zohar Levi, Matti Waterman, Iris Fried, Jacob M. Rowe, Dan Turner
Summary: Pediatric onset inflammatory bowel disease (PIBD) patients have a higher risk of developing cancer compared to non-inflammatory bowel disease (IBD) children, but the absolute risk is very low, and no significant differences in risk were found among different treatment methods in our data.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Motasem Alkhayyat, Mohammad Abureesh, Ashraf Almomani, Mohannad Abou Saleh, Mohammad Zmaili, Sara El Ouali, Emad Mansoor, Alberto Rubio-Tapia, Miguel Regueiro
Summary: In this study, a large database was used to explore the association between celiac disease and inflammatory bowel disease (IBD) and the impact of IBD treatment. The results showed a bidirectional association between celiac disease and IBD, with a stronger association observed in Crohn's disease (CD). Patients with IBD who received corticosteroids, 5-aminosalicylates, immunomodulators, or anti-tumor necrosis factor drugs had a lower association with celiac disease. Additional research is needed to understand the underlying mechanisms for the modification of celiac disease incidence by IBD therapy.
INFLAMMATORY BOWEL DISEASES
(2022)
Review
Nutrition & Dietetics
Yan Jiang, Karolin Jarr, Cosima Layton, Christopher D. Gardner, Judith E. Ashouri, Maria T. Abreu, Sidhartha R. Sinha
Summary: Despite being an important issue for patients, the impact of diet on adult inflammatory bowel disease (IBD) is not well explored, with limited guidance. Current evidence on various diets used in the treatment of IBD is summarized, with potential applications of dietary data from related immune-mediated inflammatory diseases (IMIDs) to inform providers. Multiple diets, including Mediterranean, vegetarian/vegan, and reduced-calorie/fasting diets, have shown positive results in other inflammatory diseases, suggesting potential applicability to IBD, but further well-designed clinical trials are needed for guidance.
Review
Medicine, General & Internal
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, Ioannis E. Koutroubakis
Summary: Despite advancements in inflammatory bowel disease (IBD) management, anti-TNF agents continue to be the primary treatment for Crohn's disease and ulcerative colitis. However, optimizing treatment strategies is essential due to the progressive nature of the disease and potential loss of response. This overview examines the role of therapeutic drug monitoring (TDM), combining anti-TNF with immunomodulators, and the treat-to-target approach in enhancing the efficacy and outcomes of anti-TNF treatment.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Monica State, Lucian Negreanu
Summary: There is a lack of clear definitions and guidelines for the response criteria and treatment optimization in advanced therapies for inflammatory bowel disease, leading to inconsistent treatment strategies and premature abandonment of effective therapies.
Review
Biochemistry & Molecular Biology
Samantha Gonzalez Delgado, Idalia Garza-Veloz, Fabiola Trejo-Vazquez, Margarita L. Martinez-Fierro
Summary: This study aims to integrate scientific data on the role of the intestinal microbiota in regulating gut serotonin signaling and reuptake and its involvement in the pathogenesis of IBD. It is found that the use of selective serotonin reuptake inhibitors as an adjuvant therapy can improve disease activity and extraintestinal manifestations in IBD patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Ryo Seishima, Koji Okabayashi, Hiroki Ikeuchi, Motoi Uchino, Kitaro Futami, Tatsuki Noguchi, Hiroki Ohge, Yasuhito Iseki, Kazuhiro Watanabe, Michio Itabashi, Kinya Okamoto, Yuji Toiyama, Takayuki Ogino, Masafumi Nakamura, Kazutaka Yamada, Toshifumi Wakai, Yu Sato, Hideaki Kimura, Kenichi Takahashi, Koya Hida, Yusuke Kinugasa, Fumio Ishida, Junji Okuda, Koji Daito, Fumikazu Koyama, Hideki Ueno, Takayuki Yamamoto, Seiichiro Yamamoto, Tsunekazu Hanai, Atsuo Maemoto, Junya Arakaki, Koji Komori, Yoshito Akagi, Dai Shida, Shigeki Yamaguchi, Keiji Matsuda, Kiyoshi Maeda, Toshihiro Noake, Riichiro Nezu, Shin Sasaki, Junichi Hasegawa, Eiji Sunami, Yukihide Kanemitsu, Kenji Katsumata, Kei Uehara, Tomomichi Kiyomatsu, Takeshi Suto, Shinsuke Kazama, Takeshi Yamada, Takenori Goi, Soichiro Ishihara, Yoichi Ajioka, Kenichi Sugihara
Summary: This study aimed to evaluate the impact of biologics on the risk of advanced-stage inflammatory bowel disease (IBD)-associated intestinal cancer. The results showed that in patients with Crohn's disease (CD), no drugs were significantly associated with cancer stage. However, in patients with ulcerative colitis (UC), less use of biologics, 5-aminosalicylic acid, and immunomodulators was significantly associated with advanced cancer stage. Multivariate analysis demonstrated that biologic use was significantly associated with a lower risk of advanced-stage disease.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Lorenzo Bertani, Brigida Barberio, Domenico Trico, Federico Zanzi, Daria Maniero, Linda Ceccarelli, Ilaria Marsilio, Francesca Coppini, Greta Lorenzon, Maria Gloria Mumolo, Fabiana Zingone, Francesco Costa, Edoardo Vincenzo Savarino
Summary: The study found that hospitalization for intravenous biologics treatment did not increase the risk of COVID-19 infection in patients with inflammatory bowel diseases during the COVID-19 outbreak. Additionally, there was a similar level of anxiety between patients receiving intravenous and subcutaneous drug treatments.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Anthony Buisson, Melanie Serrero, Laurie Orsat, Stephane Nancey, Pauline Riviere, Romain Altwegg, Laurent Peyrin-Biroulet, Maria Nachury, Xavier Hebuterne, Cyrielle Gilletta, Mathurin Flamant, Stephanie Viennot, Guillaume Bouguen, Aurelien Amiot, Stephane Mathieu, Lucine Vuitton, Laurianne Plastaras, Arnaud Bourreille, Ludovic Caillo, Felix Goutorbe, Guillaume Pineton De Chambrun, Alain Attar, Xavier Roblin, Bruno Pereira, Mathurin Fumery
Summary: This study compared the acceptability of different maintenance regimens in patients with inflammatory bowel disease (IBD). The results showed that the acceptability of treatment was highly influenced by the route of administration and prior medication exposures. Subcutaneous injections with intervals of 8 weeks or longer and oral intake once daily were the most accepted modalities.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Neasa Mc Gettigan, Aman Shah Afridi, Grace Harkin, Caroline Lardner, Stephen Patchett, Danny Cheriyan, Gavin Harewood, Karen Boland, Aoibhlinn O'Toole
Summary: The study aimed to identify optimal management strategies for anti-drug antibodies (ADAs) in patients receiving infliximab (IFX) to prevent therapy discontinuation. Results showed that increasing IFX dosage and adjusting combination therapy can lower rates of discontinuation of IFX, with significant cut-off values for ADA trough levels and important clinical outcomes identified through ROC curve analysis.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)